Lipid peroxidation plays an important role in Alzheimer Disease, so corresponding metabolites found in urine samples could be potential biomarkers. The aim of this work is to develop a reliable ultra-performance liquid chromatography-tandem mass spectrometry analytical method to determine a new set of lipid peroxidation compounds in urine samples.

Excellent sensitivity was achieved with limits of detection between 0.08 and 17 nmol L⁻¹, which renders this method suitable to monitor analytes concentrations in real samples. The method's precision was satisfactory with coefficients of variation around 5–17% (intra-day) and 8–19% (inter-day). The accuracy of the method was assessed by analysis of spiked urine samples obtaining recoveries between 70% and 120% for most of the analytes. The utility of the described method was tested by analyzing urine samples from patients early diagnosed with mild cognitive impairment or mild dementia Alzheimer Disease following the clinical standard criteria. As preliminary results, some analytes (17(RS)−10-epi-SC-Δ¹⁵−11-dihomo-IsoF, PGE₂) and total parameters (Neuroprostanes, Isoprostanes, Isofurans) show differences between the control and the clinical groups. So, these analytes could be potential early Alzheimer Disease biomarkers assessing the patients’ pro-oxidant condition.

脂质过氧化在阿尔茨海默病中起重要作用，因此尿液样品中发现的相应代谢产物可能是潜在的生物标志物。这项工作的目的是开发一种可靠的超高性能液相色谱-串联质谱分析方法，以确定尿液样品中的一组新的脂质过氧化化合物。

在0.08至17 nmol L ^-1的检测限范围内实现了出色的灵敏度，这使得该方法适用于监测实际样品中的分析物浓度。该方法的精密度令人满意，变异系数在5-17％（日间）和8-19％（日间）之间。该方法的准确性通过对加标尿液样品的分析进行评估，从而使大多数分析物的回收率在70％至120％之间。通过按照临床标准标准分析早期诊断为轻度认知障碍或轻度痴呆阿尔茨海默氏病的患者的尿液样品，测试了上述方法的实用性。作为初步的结果，一些分析物（17（RS）-10-外延-SC-Δ ¹⁵ -11-二高-γ-ISOF，PGE₂）和总参数（神经前列烷，异前列烷，异呋喃）显示对照组和临床组之间的差异。因此，这些分析物可能是潜在的早期阿尔茨海默氏病生物标志物，可评估患者的促氧化剂状况。